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Abstract: Cancer complexity relies on the intracellular pleiotropy of oncogenes/tumor suppressors
and in the strong interplay between tumors and micro- and macro-environments. Here we followed
a reductionist approach, by analyzing the transcriptional adaptations induced by three oncogenes
(RAS, MYC, and HDAC4) in an isogenic transformation process. Common pathways, in place of
common genes became dysregulated. From our analysis it emerges that, during the process of
transformation, tumor cells cultured in vitro prime some signaling pathways suitable for coping with
the blood supply restriction, metabolic adaptations, infiltration of immune cells, and for acquiring the
morphological plasticity needed during the metastatic phase. Finally, we identified two signatures of
genes commonly regulated by the three oncogenes that successfully predict the outcome of patients
affected by different cancer types. These results emphasize that, in spite of the heterogeneous
mutational burden among different cancers and even within the same tumor, some common hubs
do exist. Their location, at the intersection of the various signaling pathways, makes a therapeutic
approach exploitable.
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1. Introduction
Cancer is a complex disease that arises through the accumulation of specific genetic lesions,
affecting oncogenes and tumor suppressor genes. These lesions hijack transcriptional/epigenetic
machineries to reprogram the gene expression profile of the cells [1]. The final goal is to sustain a
robust proliferation, invasion, and the suppression of cell death programs. The tumorigenic process
is the consequence of the adaptations that tumor cells must achieve to overcome different crises.
Escaping senescence, suppressing apoptosis, resolving starvation from blood supply, impinging the
metabolic circuits, and evading immune surveillance represent the major achieved adaptations [2].
Cancer cells are part of a complex ecosystem. Together with fibroblasts, endothelial and the
immune cells constitute and organize the tumor microenvironment [3]. These cells establish different
interactions that are transduced and maintained by interconnected networks of signals. To unveil
this complexity, system biology approaches can be adopted to integrate genomic and epigenomic
data collected from tumor biopsies [4,5]. Moreover, the initial assumption of considering cancer as
the expansion of a monoclonal population has been recently replaced by the evidence obtained by
single-cell sequencing [6]. In each cancer, several subclones can co-exist and can expand or contract as
a function of their fitness [6].
Within this complexity, it is important to define the crucial events that can be target for a therapeutic
intervention. The social impact of the tumorigenic process must prompt us to focus all efforts in
unveiling the key oncogenic addictions for each different tumor type.
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Historically, in vitro transformation models have provided the first approach to understand the
tumorigenic process [7]. The identification of oncogenes and tumor suppressor genes and the demonstration
of the cooperation among oncogenes represent the major accomplishments of these model systems.
Traditionally, rodent cells have been largely used. However, transformation of murine cells and human cells
greatly differ [8]. Human cells are more resistant to oncogenic transformation and require more events [9].
In vitro transformation approaches frequently adopt viral oncoproteins to switch off important tumor
suppressor genes, such as RB and TP53. Nevertheless, transformation of human cells can also be obtained
in absence of viral genes [10]. An innovative version of the in vitro transformation studies is represented by
the generation of human organoids. Under a 3D growth condition and a selected microenvironment, these
primary cells can be engineered in vitro, using CRISPR/Cas9 genome editing approaches, to recapitulate
the key oncogenic lesions of the primary tumors [11].
Importantly, in vitro tumorigenic models must find validation in vivo. The resetting of the
transcriptomic output represents the major tool through which cancer cells modulate their plasticity
and adapt to the microenvironment. Hence, in this manuscript, we have compared the transcriptional
profiles of three different isogenic models of in vitro transformation. Our goal is to demonstrate
a correspondence between the in vitro transformation process and cancer development in patients.
Moreover, we would like to define a minimal gene signature, shared among different transformation
models, that could represent a useful tool to unveil the Achilles’ heel of many cancers.
2. Results
2.1. In Vitro Transformation of Human Fibroblasts Achieved by Different Oncogenes Leads to the Activation of
Both Distinct and Common Genetic Programs
In vitro transformation of human cells requires a limited number of genetic changes [7].
Viral genes such as the SV40 early region, which encodes both the large T and small t oncoproteins,
in combination with the catalytic subunit of the telomerase (hTERT) have been commonly used to
drive the immortalization and to circumvent senescence of normal human fibroblasts and kidney
cells [12]. The subsequent introduction of strong oncogenes such as RAS or MYC triggers the cellular
transformation. These cells are characterized by an anchorage independent growth and by the ability
to generate tumors when injected in immunocompromised mice [12,13].
Here, we deeply investigated the strength of the transcriptome reprogramming, triggered during
the in vitro transformation process, in predicting the outcome of different human cancers. With this
aim we compared the gene expression profiles of human foreskin fibroblasts expressing hTERT,
the early region of SV40 and subsequently transduced with HRAS/G12V [13], MYC [14], or an oncogenic
nuclear resident form of HDAC4 (HDAC4-TM) [13,15]. These oncogenes have been chosen for their
heterogeneity. As frequently reported for other oncogenic combinations [12,13], when mutations,
amplifications, or transcript dysregulations of these oncogenes were analyzed in different human
cancers, the co-occurrence of their alterations appears to be restricted to a small number of cases.
In Figure 1, we report the oncoprint of TCGA PanCancer ATLAS datasets selected among some of the
most frequent solid tumors. We included breast, colorectal, lung, prostate, stomach, and uterine cancers
(Figure 1). As expected, point mutations in RAS are not common in breast and prostate cancer [16].
Interestingly, genetic alterations in HDAC4 are more frequent in uterine and stomach cancers, with a
conspicuous incidence of truncations and point mutations of still unknown impact on the activities of
this deacetylase (Figure 1).
The simultaneous dysregulations of HDAC4, MYC, and RAS oncogenes are relatively rare.
There are some co-occurrences between HDAC4 and MYC or HDAC4 and RAS as well as between
MYC and RAS. Most frequently, patients carry alterations only in one of the three oncogenes
(Figure 1). This evidence suggests that the three oncogenes can act through completely distinct
and non-complementary mechanisms or through at least partially overlapping pathways.
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Figure 1. Summary of the genetic alterations reported for HRAS, KRAS, NRAS, MYC, and HDAC4 in
some human cancers. Oncoprints of HDAC4, HRAS, KRAS, NRAS, and MYC mutations and alterations
in the indicated tumor types. Images were cropped to highlight the alterations. Data were obtained
from the TCGA database. The heatmap was generated through cBioPortal (http://www.cbioportal.org).
The different genetic alterations are indicated by the provided color code.
2.2. RAS, MYC, and HDAC4-Mediated Oncogenic Transformation Is Marked by the Dysregulation of Common
Pathways Rather Than of Common Genes.
To prove the above enounced concept, we interrogated the gene expression profiles of
BJ-hTERT/ST/LT/MYC [14], BJ-hTERT/ST/LT/HRASG12V [13], and BJ-hTERT/ST/LT/HDAC4-S246A, S467A,
S632A [15], relatively to the isogenic pre-transformed control cells, expressing the SV40 LT and ST or
the entire early region.
By adopting as cut-off criteria 1.5-fold change and FDR < 0.05, we obtained six signatures of genes
regulated by the three oncogenes. Overall, 519 and 634 transcripts were respectively upregulated and
downregulated by MYC, 556 and 595 by RAS and finally, 551 and 979 by HDAC4.
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Few genes turned out to be commonly dysregulated by the three oncogenes. Only three genes
were upregulated either in RAS, MYC, and HDAC4 transformed cells (Figure 2A), while 22 were the
commonly repressed genes (Figure 2B).
Figure 2. Analysis of the transcriptional profiles in three different models of in vitro transformation.
(A) Venn diagram showing the number of transcripts upregulated during the transformation process in
BJ/hTERT/LT/ST cells expressing RAS, MYC, or HDAC4 as indicated. (B) Venn diagram showing the
number of transcripts downregulated during the transformation process in BJ/hTERT/LT/ST cells expressing
RAS, MYC, or HDAC4 as indicated. (C) Venn diagram showing the number of different hallmarks gene sets
significantly upregulated by RAS, MYC, and HDAC4. (D) Venn diagram showing the number of different
hallmarks gene sets significantly downregulated by RAS, MYC, and HDAC4. All the Venn diagrams were
created by using this software http://bioinformatics.psb.ugent.be/webtools/Venn/.
Although the commonly dysregulated genes are rare, the three oncogenes could influence the
same pathways through alterations of different genes, operating at different steps of the same pathway.
To prove this hypothesis, we applied the Gene Set Enrichment Analysis (GSEA) algorithm to compare
the six signatures obtained to the MSigDB HALLMARK gene sets [17,18]. The “HALLMARKS” is a
collection of 50 gene sets; each of them groups genes that display coordinate expression and represent
well-defined biological processes. Tables SIA–SIC summarize the statistically significant genes sets
identified by the analysis for the upregulated genes and Tables SIIA–SIIC for the downregulated
genes. Venn diagrams show that the three oncogenes share several gene sets, which control important
biological functions related to the transformation process. For the upregulated genes, 14 different gene
sets were commonly regulated by RAS, MYC, and HDAC4 (Figure 2C). For the repressed genes this
number increased up to 23 (Figure 2D).
In summary, although the number of genes commonly regulated in the three models of in vitro
transformation is small, the pathways and the biological processes under the influences of HDAC4,
RAS, and MYC testify a convergence towards common strategies of hijacking specific cellular responses.
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2.3. Identification of the Pathway Reprogramming Core that Defines the Common Trait of the in Vitro
Transformation Process
Having found that the three transformation models influence common gene sets, we next analyzed
which genes were under the regulation of the three oncogenes in the different gene sets.
Figure 3 shows the result of such analysis for the upregulated genes. As above mentioned, only
three genes (DOCK4, G0S2, SRPX) were commonly induced by the three oncogenes. These genes are
represented in more than one gene set. The Venn diagrams illustrate also the common genes among
two models of in vitro transformation (Figure 3). Interestingly, the gene set “p53 pathway” includes
all the three genes. Although no other genes were in common between RAS and MYC or RAS and
HDAC4, all genes (n = 9) were in common between MYC and HDAC4. This observation suggests that
HDAC4 and MYC share similar strategies to dysregulate the p53 pathway. Another relevant gene
set is the “inflammatory response”. Here common genes were not identified. However, this cellular
response is equally modulated by all three oncogenes, with a similar number of genes. Some of them
are in common between RAS and HDAC4 (n = 2), RAS and MYC (n = 2), and MYC and HDAC4 (n = 3).
In the case of the gene set “glycolysis” several genes are under the influence of RAS and a good overlap
is observed with MYC (n = 5). By contrast, HDAC4 shows a peculiar influence on this metabolic gene
set, possibly reflecting its non-conventional activities on the metabolism of the transformed cells [19].
When we analyzed the repressed genes, the number of statistically significant hallmarks gene sets
was higher (n = 23) (Figure 4 and Tables SIIA–SIIC). The gene set “epithelial-mesenchymal transition”
scored the highest number of common hubs (n = 5). In addition, a significant number of genes were
similarly dysregulated by RAS and HDAC4 (n = 7) and by MYC and HDAC4 (n = 5). The EMT gene
set was the most statistically significant enriched gene set in the RAS and HDAC4 transformed cells,
whereas in MYC-transformed it scored the fourth position. An opposite behavior was observed for the
gene set “complement”. The total number of genes regulated was 46 but only 2 genes were in common
between RAS and MYC and HDAC4 and MYC. This observation indicates that the complement
pathway is targeted through alternative mechanisms in the three models of in vitro transformation.
Other statistically significant repressed gene sets are the interferon-α (IFNα) and the interferon-γ
(IFNγ) responses. In RAS-transformed cells they resulted the second and the third top hits, respectively,
whereas in MYC-transformed cells the second and the first. Finally, in the case of HDAC4 they scored
as the seventh and the third hits.
Only three genes were commonly repressed in the IFNs hallmarks gene sets: ARID5B, ELF1,
and MX1. The last was present in both the IFNα and the IFNγ gene sets. When RAS and MYC were
compared, 20 genes were in common for the IFNγ response and 15 in the case of the IFNα. On the other
side, HDAC4 shows stronger similarities with MYC. Nine genes belonging to IFNγ and to IFNα gene
sets were in common between MYC and HDAC4 in IFNγ as well as in IFNα gene sets. Few similarities
were found between HDAC4 and RAS, with only a gene in common for IFNγ (Figure 4).
In summary, this analysis indicates the IFNα and IFNγ signaling are significantly and robustly
repressed in different models of in vitro transformation. This can be due to: (i) the key role that the
repression of the pathways plays in the transformation process, as previously reported [20–24]; (ii) a
certain degree of purifying selection that supervise the conservation of IFN signaling [25].
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Figure 3. Hallmarks and genes commonly upregulated by the three oncogenes (HDAC4, RAS, MYC)
during the in vitro transformation process. Venn diagram showing different sets of hallmarks and the
number of upregulated genes, which are shared by HDAC4, RAS, and MYC.
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Figure 4. Hallmarks and genes commonly downregulated by three oncogenes (HDAC4, RAS, MYC)
during the in vitro transformation process. Venn diagram showing different sets of hallmarks and
number of downregulated genes that were commonly shared by HDAC4, RAS, and MYC.
2.4. Definition of the Minimal Signatures Regulated during in Vitro Transformation
The final goal of our approach is to verify if the pathways dysregulated during the in vitro
transformation can predict the outcome of malignant cancers in patients. For this reason, we extracted
three signatures: Two for the repressed and one for upregulated genes (Table 1). Both signatures are
made up of genes commonly and significantly upregulated or downregulated by the three oncogenes.
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Table 1. List of the common genes and of the relative signatures modulated during the in vitro
transformation process.
GENE SIGNATURE HALLMARK
DOCK4 Upregulated Complement/Spindle
G0S2 Upregulated TNF-NFKB/KRAS
SRPX Upregulated Hypoxia
CDH11 Downregulated A EMT/APICAL
DKK1 Downregulated A EMT
GREM1 Downregulated A EMT
MYLK Downregulated A Adipogenesis/Myogenesis/EMT
SPRY2 Downregulated A KRAS
ARID5B Downregulated B Androgen/IFNγ
DUSP4 Downregulated B TNFα-NFKB
ELF1 Downregulated B IFNα/ESTROGEN
LPAR1 Downregulated B Inflammation/UV
MX1 Downregulated B IFNα/IFNγ
SOCS2 Downregulated B IL2-STAT5
TNFRSF11B Downregulated B EMT/APICAL
The signature of the upregulated genes groups DOCK4, G0S2, and SRPX (Table 1). DOCK4 encodes
for a guanine nucleotide exchange factors that participates in the regulation of cell adhesion and membrane
trafficking [26,27]. It is reported to be mutated in cancer [26] and to influence cancer aggressiveness through
the modulation of WNT and TGF-β pathways [28,29]. Since also anti-proliferative activities have been
reported, its oncogenic potential seems to be context specific [30,31].
G0S2 (G0/G1 switch gene 2) encodes for a potent inhibitor of adipose triglyceride lipase. In this
manner, G0S2 acts as a master regulator of the tissue-specific balance of triglyceride storage vs.
mobilization [32]. Correlations with cancer are unclear with anti-proliferative effects described
by some reports [33–35]. Finally, SRPX (sushi repeat containing protein X-linked), known also as
ETX1 or DRS, was initially isolated as deleted in patients with X-linked retinitis pigmentosa [36],
as well as downregulated by v-src [37]. A tumor suppressive activity for SRPX was proposed [38].
Moreover, its expression seems to be downregulated in different aggressive cancers [39–41].
For the repressed genes we selected two different signatures. The first signature (repressed
signature A) includes five genes (CDH11, DKK1, GREM1, MYLK, SPRY2). These genes do not belong to
the inflammatory and interferon gene sets (Table 1). A second signature of genes (repressed signature
B) groups the remaining commonly repressed genes that belong to inflammatory-immune responses
(ARID5B, DUSP4, ELF1, LPAR1, MX1, SOCS2, TNFRSF11B).
2.5. High mRNA Levels of the Upregulated Genes Correlate with Reduced Patients’ Survival in a Group of
Different Tumors
In order to understand if the identified signatures can predict cancer aggressiveness and patients’
outcome, they were used to interrogate the survival data of 32 cancer types deposited in the Cancer
Genome Atlas (TCGA).
For the upregulated genes, we segregated the patients in two groups. The first group is
characterized by high expression levels of the signature (above the third quartile). The second group is
characterized by moderated upregulation, unperturbed or repressed expression of the signature (below
the third quartile). Figure 5A illustrates that in six different cancer types (colorectal adenocarcinoma,
kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, testicular
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germ cell tumors, and uveal melanoma) high levels of DOCK4, G0S2, and SRPX significantly correlate
with a worst survival.
Figure 5. High mRNA levels of upregulated genes during in vitro transformation process influence
patients’ survival. (A) Kaplan-Meier survival analysis related to the three upregulated genes DOCK4,
G0S2, SRPX. All cases were analyzed and clustered into two groups according to DOCK4, G0S2,
and SRPX expression levels. High levels of expression group (> the third quartile/high expressing)
compared to all other cases (< the third quartile/low expressing). Cases were: Colorectal adenocarcinoma
(all n = 382, high expressing n = 95), kidney chromophobe (all n = 65, high expressing n = 16), kidney
renal clear cell carcinoma (all n = 510, high expressing n = 127), kidney renal papillary cell carcinoma
(all n = 283, high expressing n = 70), testicular germ cell tumors (all n = 149, high expressing n = 37),
and uveal melanoma (all n = 80, high expressing n = 20). (B) Kaplan-Meier survival analysis related
to G0S2 in adrenocortical carcinoma (ACC). High level expression (above the third quartile) of G0S2
in ACC were observed in 19 cases. All cases were n = 78. (C) Kaplan-Meier survival analysis related
to DOCK4 and SRPX in ACC. High level expression (> the third quartile) of DOCK4 and SRPX were
observed in 19 cases, all cases were n = 78.
On the opposite high levels of the signature predicts a better overall survival in adrenocortical
carcinoma (ACC) (Figure 5B). This behavior could depend on G0S2. In fact in ACC, which is a rare,
aggressive malignancy, G0S2 hypermethylation is a hallmark of rapidly recurrent or fatal disease,
amenable to targeted assessment using routine molecular diagnostics [35]. Very low levels of G0S2
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mRNA expression characterize tumors with G0S2 hypermethylation. Although low G0S2 expression
marks 40% of ACC and independently predicts shorter disease-free and overall survival, the role of
this gene in adrenocortical biology is still unknown [42]. To confirm this data, we repeated the survival
analysis without the G0S2 gene. In this case the positive correlation with ACC survival was abrogated
(Figure 5C). For the remaining 25 cancer types the signature failed to predict any patients’ survival.
2.6. High Levels of DOCK4, G0S2, and SRPX Expression Are Related to Worse Survival in Similar but also
Different Tumor Types
The influence of G0S2 methylation on cancer mortality is peculiar of ACC. As expected from the
in vitro transformation models, in many other tumors (n = 9) high levels of G0S2 mRNA are indicative
of a reduced survival (Figure 6).
Figure 6. High levels of G0S2 expression correlate with reduced survival in different cancer types.
TCGA survival data analysis on tumors grouped for high levels of G0S2 expression alone (> the third
quartile/high expressing) compared to all other cases (< the third quartile/low expressing). Cases were:
Adrenocortical carcinoma (all n = 78, high expressing n = 19), cervical squamous cell carcinoma (all
n = 294, high expressing n = 73), colorectal adenocarcinoma (all n = 592, high expressing n = 148), kidney
renal clear cell carcinoma (all n=510, high expressing n=127), kidney renal papillary cell carcinoma (all
n = 283, high expressing n = 70), brain low grade glioma (all n = 514, high expressing n = 128), lung
adenocarcinoma (all n = 510, high expressing n = 127), lung squamous cell carcinoma (all n = 484, high
expressing n = 121), stomach carcinoma (all n = 412, high expressing n = 103), and uveal melanoma (all
n = 80, high expressing n = 20).
Int. J. Mol. Sci. 2019, 20, 6283 11 of 22
To verify whether G0S2 is the key gene in predicting patients’ survival, we repeated the analysis
for DOCK4 and SRPX. High levels of DOCK4 correlates with a reduced survival in five different
tumors (colorectal, kidney chromophobe, brain low grade glioma, stomach adenocarcinoma, and uveal
melanoma) and with a better prognosis in two cancer types (mesothelioma and skin cutaneous
melanoma) (Figure S1). Increased levels of SRPX correlates with an increased hazardous rate in
seven different cancer types (bladder, colorectal, head and neck squamous carcinoma, kidney renal
clear cell and papillary carcinomas, thyroid carcinoma, and uterus corpus endometrial carcinoma).
Conversely, it predicts a better outcome in melanoma (Figure S2). This analysis suggests that the three
upregulated genes could exert independent activities to influence cancer aggressiveness.
2.7. A Group of Genes Repressed during in Vitro Transformation Predicts Patients’ Survival.
Next, we interrogated the TCGA survival data with the repressed signature A. The patients were
segregated in two groups accordingly to the median value of expression of the signature. In two
different cancer types, high levels of the signature correlate with increased survival, while in other six
cancer types high levels of the same signature correlate with reduced survival. Hence, we discarded
this signature for further analysis.
A different result was obtained with the repressed signature B that groups inflammatory and
interferon genes. Low levels of the repressed signature correlate with a worst prognosis in five cases:
Kidney chromophobe carcinoma, kidney clear cell carcinoma, sarcoma, skin cutaneous melanoma,
and uterine carcinosarcoma (Figure 7A). On the opposite, low levels of this signature predict a better
outcome in patients with brain lower grade glioma and ovarian serous cystadenocarcinoma (Figure 7B).
For simplicity we named this signature “oncogene-repressed inflammatory signature”.
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Figure 7. Patients’ survival and expression levels of oncogene-repressed inflammatory signature.
(A) Kaplan-Meier survival analysis related to the oncogene-repressed inflammatory signature. All cases
were analyzed and clustered into two groups according to median expression levels (high median;
expression levels > the median and low median; expression levels< the median). Cases were: Kidney
chromophobe (all n = 65, high expressing n = 32), kidney renal clear cell carcinoma (all n = 510, high
expressing n = 255), sarcoma (all n = 253, high expressing n = 126), skin cutaneous melanoma (all
n = 443, high expressing n = 221), and uterine carcinosarcoma (all n = 57, high expressing n = 28).
(B) Kaplan-Meier survival analysis related to the oncogene-repressed inflammatory signature. All cases
were analyzed and clustered into two groups according to median expression levels (high median;
expression levels > the median and low median; expression levels < the median). Cases were: Brain
low grade gliomas (all n = 514, high expressing n = 257) and ovarian serous cystadenocarcinoma (all
n = 300, high expressing n = 150).
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2.8. Inflammatory Genes Repressed during the in Vitro Transformation Process and Tissue-Infiltrating
Immune Cells
Tumors are characterized by a variegated abundance of tissue infiltrating immune cells, which can
influence the prognosis [43]. Since the oncogene-repressed inflammatory signature comprises many
inflammatory genes, our in vivo analysis could be influenced by the presence of tumor infiltrating
immune cells. Recent studies have shown that the abundance of immune cells in tissue transcriptomic
data can be predicted by specific mRNA signatures [44].
We applied the microenvironment cell populations-counter (MCP-counter) to evaluate the
contribution of different immune cells to the survival outcomes of patients analyzed for the
oncogene-repressed inflammatory signature. With the exclusion of kidney chromophobe, uterine
carcinosarcoma, and ovarian serous cystadenocarcinoma, in the other cancer types the survival was
also influenced by the presence of immune cells, although with different outcomes (Figures S3 and S4).
Prognosis of skin cutaneous melanoma, sarcoma, and brain low grade glioma (LGG) is influenced by
the infiltration of different subtypes of immune cells. These tumors behave differentially, with only
LGG showing a worst outcome. On the contrary, the better outcome of kidney renal cell carcinoma
results significantly and specifically associated with the presence of myeloid dendritic cells (Figure S4).
In conclusion, although in some tumor types the repression of the inflammatory signature and the
resulting reduced patients’ survival can be specifically ascribed to the transcriptional reprogramming of
the neoplastic cells; in other tumors, we cannot exclude a contribution of the immune cells. These cells
may have been isolated along with the tumor tissue and thus contribute to the transcriptional landscape
as reported by the TCGA data.
2.9. Oncogene-Repressed Inflammatory Signature Provides an Additional Contribution to Overall Survival
As a final analysis, we decided to evaluate the impact on patients’ survival of both the tumor
infiltrating immune cells and of the expression levels of the oncogene-repressed inflammatory signature.
The analysis was restricted to tumor types that showed significant correlations between the overall
survival and the presence of the immune cell infiltrates (Figures S3 and S4).
The three tumor types analyzed were LGG, skin cutaneous melanoma, and sarcoma (Figure 8).
In LGG, the coexistence of high levels of expression of the oncogene-repressed inflammatory signature
and the presence of immune cells, particularly of T cells, cytotoxic lymphocytes and neutrophils
represent a negative prognostic condition (Figure 8B,C,G). In agreement with our data, strong
correlations between the risk score and T cells, macrophage-related immune response, as well as the
expression of immunomodulators were recently reported in LGGs [3,45].
Interestingly, in sarcoma and melanoma tumors where high levels of the oncogene-repressed
inflammatory signature correlate with an increased survival, two different behaviors can be appreciated.
In sarcoma the presence of immune cells is dominant. In fact, when immune cell infiltrates (particularly
CD8 T cells and cytotoxic lymphocytes) are observed, increased survival is maintained, also in the
presence of low levels of the oncogene-repressed inflammatory signature (Figure 8E,G). In contrast,
in skin cutaneous melanoma low expression levels of the signature are sufficient to reduce the overall
survival (Figure 8A,C,D,F,G). In melanoma, the best prognosis is observed in the presence of high
expression of the oncogene-repressed inflammatory signature and the concomitant presence of immune
cells, particularly T cells, NK, CD8 T cells, and cytotoxic lymphocytes.
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Figure 8. The contribution of infiltrating immune/inflammatory cells to overall survival. Kaplan-Meier
survival analysis related to the immune/inflammatory signature and the infiltration of different
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immune/inflammatory cells. Infiltrating immune/inflammatory cells were defined as described
in materials and methods. Patients were grouped high/high (high levels of both infiltrating
cells and immune signature), high/low (high levels of infiltrating cells and low levels of the
oncogene-repressed inflammatory signature), low/high (low levels of infiltrating cells and high levels
of the oncogene-repressed inflammatory signature), and as low/low (low levels of both infiltrating cells
and of the oncogene-repressed inflammatory signature). The four groups were generated according
to median expression levels of the two signatures. Cases: (A) Sarcoma (all = 253, high/high = 75,
high/low = 51, low/high = 51, low/low = 76) and skin cutaneous melanoma (all = 428, high/high = 133,
high/low = 82, low/high = 82, low/low = 131). (B) Brain low grade glioma (all = 512, high/high = 155,
high/low = 102, low/high = 101, low/low = 154). (C) Brain low grade glioma (all = 512, high/high = 164,
high/low = 92, low/high = 92, low/low = 164) and skin cutaneous melanoma (all = 428, high/high = 148,
high/low = 66, low/high = 67, low/low = 147). (D) Skin cutaneous melanoma (all = 428, high/high = 143,
high/low = 72, low/high = 72, low/low = 141). (E) Sarcoma (all = 253, high/high = 70, high/low = 56,
low/high = 56, low/low = 71) and skin cutaneous melanoma (all = 428, high/high = 136, high/low = 77,
low/high = 79, low/low = 136). (F) Brain low grade glioma (all = 512, high/high = 164, high/low = 93,
low/high = 92, low/low = 163) and skin cutaneous melanoma (all = 428, high/high = 140, high/low = 73,
low/high = 75, low/low = 140). (G) Brain low grade glioma (all = 512, high/high = 153, high/low = 104,
low/high = 103, low/low = 152), sarcoma (all = 253, high/high = 74, high/low = 52, low/high = 52,
low/low = 75) and skin cutaneous melanoma (all = 428, high/high = 142, high/low = 74, low/high = 73,
low/low = 139). (H) Kidney renal clear cell carcinoma (all = 510, high/high = 132, high/low = 123,
low/high = 123, low/low = 132), sarcoma (all = 253, high/high = 70, high/low = 56, low/high = 56,
low/low = 71) and skin cutaneous melanoma (all = 428, high/high = 126, high/low = 89, low/high = 89,
low/low = 124).
3. Discussion
In this manuscript, we compared three isogenic models of in vitro transformation and we identified
minimal signatures that characterize the transformation process. We figured out that most of the
oncogenic programs driven by the three oncogenes rely on the activation of common pathways.
Curiously, these pathways seem to be activated through alternative/complimentary mechanisms, as the
modulated transcripts deeply differ and overlap only partially. This could be expected as RAS and
MYC in cancer establish a cooperation based on the integration rather than on the intersection of their
genetic programs [46]. Moreover, this evidence suggests that the third selected oncogene, HDAC4,
triggers a different transformation process, as suggested previously [19,47–50]. However, even if
through alternative roads, the three oncogenes converge on some common hubs [2].
A minimal signature of three upregulated transcripts identified through our analysis successfully
predict worse prognosis in some cancers. Among these genes emerges G0S2. This inhibitor of adipose
triglyceride lipase governs lipolysis and fatty acid (FA) availability. G0S2 is abundantly expressed
in adipose tissue and G0S2 transgenic mice experience difficulties in shifting from carbohydrate to
FA oxidation during fasting [51]. In vivo studies have indicated that G0S2 could ensure the usage of
glycogen-derived glucose as the primary source of rapid energy output [32,51]. This influence could
be relevant for the metabolic adaptation of cancer cells. However, preliminary studies have provided
conflicting data on a role of G0S2 in cancer cells [34,52–54]. Our discovery about the existence of strong
correlations between G0S2 levels and patients’ survival in different cancers suggests the needing of
a more extensive investigation about the impact of this gene on the metabolism and proliferation of
transformed cells.
Repression of interferon-inducible genes is a well-known feature of the RAS-dependent
transformation process [55–59]. Similarly, correlations between MYC and interferon have been
known since a long time. Initially, it was discovered that IFNs can regulate MYC expression [60,61].
Subsequently, a suppressive activity of MYC on IFN signaling was reported [62]. This repressive
influence was further proved by transcriptomic studies [63–67]. The recent discovery that the targeting
of MYC through an epigenetic therapy provides an important advantage for an efficient immunotherapy
could represent an important clinical perspective of all these studies [68,69].
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Our results justify the inclusion of HDAC4 in the group that comprises two historically oncogenes
for being similarly able to repress IFN genes during the transformation process. In the in vitro
model of transformation, the presence of SV40 genes—which promote the expression of the interferon
response [70]—could overestimate the repressive influence of the cellular oncogenes on this pathway.
Nevertheless, alterations of the interferon genes were observed also in vivo and independently from the
presence of the immune cells (Figure 8). Switching off the IFN and the inflammatory responses could
provide a double advantage to the transformed cells, both in a cell autonomous and non-autonomous
manner. It can favor the transformation process, by limiting tumor suppressive actions (such as
apoptosis), and it can influence the tumor microenvironment and the immune response [71]. In vivo
experiments on murine models of cancer have clarified that, in the initial tumorigenic steps, a strong
inflammatory environment is promoted by the cancer cells themselves [72]. The release of chemokines,
cytokines, and growth factors, as a consequence of the DNA damage accumulated during the early
transformation process, promotes the infiltration and proliferation of immune cells that set up the
first line of anti-cancer extracellular responses [73]. When full transformation is achieved, cancer
cells drive a strong anti-inflammatory response, through intracellular clues—such as the activation of
the IL10-Stat3 pathway and the release of extracellular molecules—which recall immune suppressor
cells [74]. The balance of the anti-tumor response is then further compromised by the effect of the
stroma and of the microenvironment, with the involvements of cancer associated fibroblasts (CAFs)
and of tumor associated macrophages (TAMs).
It is curious that these two steps are exactly recapitulated during the in vitro transformation, with
the arising of a type I IFN response during oncogene induced senescence or in the steps that come
immediately before the full oncogenic conversion. After this step, the anti-inflammatory responses
become predominant, as examined in this manuscript. The concept that some of these key features
are triggered also in cancer cells cultured in petri dish suggests that the microenvironment acts by
sculpting pathways that are already well established and poised in tumor cells in face of intracellular
survival needs [75].
In conclusion, our analysis evidences that different oncogenes use common pathways to reach
malignancy and to set up a barrier against the immune aggression.
4. Materials and Methods
4.1. Data Retrieval and Analysis
The transcriptional profiles of the three isogenic transformation models were obtained by
re-analyzing the datasets GSE17941 [13], GSE72530 [14], and GSE120040 [15] deposited as raw
files in GEO (Gene Expression Omnibus). The CEL files were processed with affy package in
R [76]. Multiple callings coming from redundant probes were reduced to a single signal per gene
by using Unigene ID centered CDFs (Chip Description Files) retrieved from the Molecular and
Behavioral Neuroscience Institute Microarray Lab (URL: http://brainarray.mbni.med.umich.edu/
Brainarray/Database/CustomCDF/genomic_curated_CDF.asp) [77]. RMA algorithm was used for
normalization [78]. In the three datasets selected, the hybridization was done on three different
Affymetrix chips (platforms HG-U133A_2, HuGene-1_0-st-v1 and Clariom_S). For the identification of
differentially expressed genes (DEGs), the limma package [79] was used. The calling of significance was
based on a 1.5-fold change/FDR < 0.05 criteria. In each dataset, the transformation model represented by
pre-transformed BJ cells expressing RAS G12V (GSE17941) or MYC (GSE72530) or HDAC4 (GSE120040)
was compared to the pre-transformation model which is represented by BJ fibroblasts expressing
hTERT, LT, and ST SV40 genes.
4.2. Enrichment Analysis
The “HALLMARK” collection of 50 gene sets deposited in the Molecular Signatures Database
(MSigDB) (subject) was interrogated with the three DEG lists generated (query). The MSigDB analysis
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tool (Broad Institute (http://www.broadinstitute.org/gsea/msigdb/index.jsp) algorithm was used to
score the overlap between queries and subjects. The identified hits were ranked by the enrichment
score and the p-value (FDR < 0.05) [17,18].
4.3. Generation of the Signatures of Transformation
The signature of the induced genes includes three genes that were significantly upregulated
in the three selected models of transformation. The signature of the repressed genes includes
13 genes commonly downregulated in the three models of transformation. This signature was
further sub-divided in sub-signatures A and B, where A includes six genes that do not belong to the
HALLMARK gene sets “inflammation” and “interferon response” and B includes the other seven genes.
4.4. Analysis of Survival
mRNA expression data coming from RNAseq studies and normalized by the
expectation-maximization (RSEM) method and patients’ clinical data about 32 cancer studies were
retrieved from TCGA, using the R package cgdsr [80]. Hits corresponding to patients with incomplete
expression or survival data were discarded. The final created dataset groups 11,424 samples belonging to
individual censored patients, distributed as follows: Adrenocortical Carcinoma (ACC, n = 93), Bladder
Urothelial Carcinoma (BLCA, n = 411), Breast Invasive Carcinoma (BRCA, n = 1108), Cervical Squamous
Cell Carcinoma (CESC, n = 310), Cholangiocarcinoma (CHOL, n = 51), Colorectal Adenocarcinoma
(COADREAD, n = 640), Diffuse Large B-Cell Lymphoma (DLBC, n = 48), Esophageal Carcinoma (ESCA,
n = 186), Glioblastoma Multiforme (GBM, n = 615), Head and Neck Squamous Cell Carcinoma (HNSC,
n = 530), Kidney Chromophobe (KICH, n = 66), Kidney Renal Clear Cell Carcinoma (KIRC, n = 538),
Kidney Renal Papillary Cell Carcinoma (KIRP, n = 293), Acute Myeloid Leukemia (LAML, n = 200),
Brain Lower Grade Glioma (LGG, n = 530), Liver Hepatocellular Carcinoma (LIHC, n = 442), Lung
Adenocarcinoma (LUAD, n = 588), Lung Squamous Cell Carcinoma (LUSC, n = 511), Mesothelioma
(MESO, n = 87), Ovarian Serous Cystadenocarcinoma (OV, n = 609), Pancreatic Adenocarcinoma
(PAAD, n = 186), Pheochromocytoma and Paraganglioma (PCPG, n = 178), Prostate Adenocarcinoma
(PRAD, n = 499), Sarcoma (SARC, n = 265), Skin Cutaneous Melanoma (SKCM, n = 480), Stomach
Adenocarcinoma (STAD, n = 478), Testicular Germ Cell Cancer (TGCT, n = 156), Thyroid Carcinoma
(THCA, n = 516), Thymoma (THYM, n = 124), Uterine Corpus Endometrial Carcinoma (UCEC, n = 549),
Uterine Carcinosarcoma (UCS, n = 57), Uveal Melanoma (UVM, n = 80). For each sample/patient,
the median expression values of the investigated signatures were calculated. According to these
values, patients were divided in two groups characterized by high or low expression of the signatures.
The Kaplan-Meier survival analysis was performed by using the survival package in R [81].
4.5. Estimation of the Contribution/Perturbation of the Immune Infiltration to the Survival Analysis
The infiltration of immune cells in the tumor biopsies was evaluated by using MCP counter
method [44]. Briefly, immunological signatures were retrieved by using the R package MCPcounter.
The previously described dataset of 11,424 samples was interrogated with these signatures [44] and
each sample was associated to the median value of expression of each signature. According to these
values, patients were segregated in two groups and the Kaplan-Meier method was applied to calculate
the survival rate.
To evaluate the contribution/disturbance of the inflammatory infiltrate to the prediction of survival
based on the transformation signatures, patients were divided into four groups accordingly to the
expression levels of genes belonging to the MCPcounter signatures and to the transformation signatures:
High-high (high levels of both), high-low (high MCP/low transformation), low-low (low levels of both),
or low-high (low MCP-high transformation).
The ‘survfit’ function and the ‘survdiff’ function were used to generate the Kaplan-Meier curves
and to calculate the significance.
Int. J. Mol. Sci. 2019, 20, 6283 18 of 22
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/20/24/6283/s1.
Author Contributions: E.D.G. Methodology, investigation, formal analysis, writing—original draft preparation;
R.P. Methodology, investigation, data curation, formal analysis; H.P. Writing—original draft preparation,
methodology, visualization; C.B. Conceptualization, writing—original draft preparation, writing—review and
editing, visualization, supervision, project administration, funding acquisition.
Funding: This study was supported by COLONACT from LR 17/2014 regione Friuli Venezia-Giulia and European
Union, European Regional Development Fund and Interreg V-A Italia-Austria 2014-2020 ITAT1054 (Program EPIC
CUP G24I19001250007) to C.B.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. You, J.S.; Jones, P.A. Cancer Genetics and Epigenetics: Two Sides of the Same Coin? Cancer Cell 2012, 22,
9–20. [CrossRef] [PubMed]
2. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. Cell 2011, 144, 646–674. [CrossRef]
[PubMed]
3. Thorsson, V.; Gibbs, D.L.; Brown, S.D.; Wolf, D.; Bortone, D.S.; Ou Yang, T.-H.; Porta-Pardo, E.; Gao, G.F.;
Plaisier, C.L.; Eddy, J.A.; et al. The Immune Landscape of Cancer. Immunity 2018, 48, 812–830. [CrossRef]
[PubMed]
4. Sompairac, N.; Nazarov, P.V.; Czerwinska, U.; Cantini, L.; Biton, A.; Molkenov, A.; Zhumadilov, Z.; Barillot, E.;
Radvanyi, F.; Gorban, A.; et al. Independent Component Analysis for Unraveling the Complexity of Cancer
Omics Datasets. Int. J. Mol. Sci. 2019, 20, 4414. [CrossRef] [PubMed]
5. Laubenbacher, R.; Hower, V.; Jarrah, A.; Torti, S.V.; Shulaev, V.; Mendes, P.; Torti, F.M.; Akman, S. A systems
biology view of cancer. Biochim. Biophys. Acta Rev. Cancer 2009, 1796, 129–139. [CrossRef]
6. Kuipers, J.; Jahn, K.; Beerenwinkel, N. Biochimica et Biophysica Acta Advances in understanding tumour
evolution through single-cell sequencing. BBA Rev. Cancer 2017, 1867, 127–138.
7. Hahn, W.C.; Counter, C.M.; Lundberg, A.S.; Beijersbergen, R.L.; Brooks, M.W.; Weinberg, R.A. Creation of
human tumour cells with defined genetic elements. Nature 1999, 400, 464–468. [CrossRef]
8. Knudson, A.G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 2001, 1, 637–641. [CrossRef]
9. Rangarajan, A.; Weinberg, R.A. Comparative biology of mouse versus human cells: Modelling human cancer
in mice. Nat Rev. Cancer 2003, 3, 952–959. [CrossRef]
10. Boehm, J.S.; Hession, M.T.; Bulmer, S.E.; Hahn, W.C. Transformation of Human and Murine Fibroblasts
without Viral Oncoproteins. Mol. Cell. Biol. 2005, 25, 6464–6474. [CrossRef]
11. Drost, J.; van Boxtel, R.; Blokzijl, F.; Mizutani, T.; Sasaki, N.; Sasselli, V.; de Ligt, J.; Behjati, S.; Grolleman, J.E.;
van Wezel, T.; et al. Use of CRISPR-modified human stem cell organoids to study the origin of mutational
signatures in cancer. Science 2017, 358, 234–238. [CrossRef] [PubMed]
12. Hahn, W.C.; Weinberg, R.A. Rules for Making Human Tumor Cells. N. Engl. J. Med. 2002, 347, 1593–1603.
[CrossRef] [PubMed]
13. Hirsch, H.A.; Iliopoulos, D.; Joshi, A.; Zhang, Y.; Jaeger, S.A.; Bulyk, M.; Tsichlis, P.N.; Shirley Liu, X.;
Struhl, K. A Transcriptional Signature and Common Gene Networks Link Cancer with Lipid Metabolism
and Diverse Human Diseases. Cancer Cell 2010, 17, 348–361. [CrossRef] [PubMed]
14. Malysheva, V.; Mendoza-parra, M.A.; Saleem, M.M.; Gronemeyer, H. Reconstruction of gene regulatory
networks reveals chromatin remodelers and key transcription factors in tumorigenesis. Genome Med. 2016, 8,
57. [CrossRef] [PubMed]
15. Paluvai, H.; Di Giorgio, E.; Brancolini, C. Unscheduled HDAC4 repressive activity in human fibroblasts
triggers TP53-dependent senescence and favors cell transformation. Mol. Oncol. 2018, 12, 2165–2181.
[CrossRef] [PubMed]
16. Makridakis, N.M.; Caldas Ferraz, L.F.; Reichardt, J.K.V. Genomic analysis of cancer tissue reveals that somatic
mutations commonly occur in a specific motif. Hum. Mutat. 2009, 30, 39–48. [CrossRef] [PubMed]
17. Daly, M.J.; Patterson, N.; Mesirov, J.P.; Golub, T.R.; Tamayo, P.; Spiegelman, B. PGC-1α-responsive genes
involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003,
34, 267–273.
Int. J. Mol. Sci. 2019, 20, 6283 19 of 22
18. Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.;
Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for
interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [CrossRef]
19. Peruzzo, P.; Comelli, M.; Di Giorgio, E.; Franforte, E.; Mavelli, I.; Brancolini, C. Transformation by different
oncogenes relies on speci fi c metabolic adaptations. Cell Cycle 2016, 15, 2656–2668. [CrossRef]
20. Perucho, M.; Esteban, M. Inhibitory effect of interferon on the genetic and oncogenic transformation by viral
and cellular genes. J. Virol. 1985, 54, 229–232.
21. Samid, D.; Flessate, D.M.; Friedman, R.M. Interferon-induced revertants of ras-transformed cells: Resistance
to transformation by specific oncogenes and retransformation by 5-azacytidine. Mol. Cell. Biol. 1987, 7,
2196–2200. [CrossRef] [PubMed]
22. Kim, T.Y.; Lee, K.-H.; Chang, S.; Chung, C.; Lee, H.-W.; Yim, J.; Kim, T.K. Oncogenic Potential of a Dominant
Negative Mutant of Interferon Regulatory Factor 3. J. Biol. Chem. 2003, 278, 15272–15278. [CrossRef]
[PubMed]
23. Critchley-Thorne, R.J.; Yan, N.; Nacu, S.; Weber, J.; Holmes, S.P.; Lee, P.P. Down-Regulation of the Interferon
Signaling Pathway in T Lymphocytes from Patients with Metastatic Melanoma. PLoS Med. 2007, 4, e176.
[CrossRef] [PubMed]
24. Katlinskaya, Y.V.; Katlinski, K.V.; Yu, Q.; Ortiz, A.; Beiting, D.P.; Brice, A.; Davar, D.; Sanders, C.;
Kirkwood, J.M.; Rui, H.; et al. Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced
Senescence and Mediates Melanoma Development and Progression. Cell Rep. 2016, 15, 171–180. [CrossRef]
[PubMed]
25. Manry, J.; Laval, G.; Patin, E.; Fornarino, S.; Itan, Y.; Fumagalli, M.; Sironi, M.; Tichit, M.; Bouchier, C.;
Casanova, J.-L.; et al. Evolutionary genetic dissection of human interferons. J. Exp. Med. 2011, 208, 2747–2759.
[CrossRef] [PubMed]
26. Yajnik, V.; Paulding, C.; Sordella, R.; McClatchey, A.I.; Saito, M.; Wahrer, D.C.R.; Reynolds, P.; Bell, D.W.;
Lake, R.; van den Heuvel, S.; et al. DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell 2003,
112, 673–684. [CrossRef]
27. Kawada, K.; Upadhyay, G.; Ferandon, S.; Janarthanan, S.; Hall, M.; Vilardaga, J.-P.; Yajnik, V. Cell Migration
Is Regulated by Platelet-Derived Growth Factor Receptor Endocytosis. Mol. Cell. Biol. 2009, 29, 4508–4518.
[CrossRef]
28. Yu, J.; Tai, Y.; Jin, Y.; Hammell, M.C.; Wilkinson, J.E.; Roe, J.; Vakoc, C.R.; Van Aelst, L. TGF-β/Smad signaling
through DOCK4 facilitates lung adenocarcinoma metastasis. Genes Dev. 2015, 29, 250–261. [CrossRef]
29. Westbrook, J.A.; Wood, S.L.; Cairns, D.A.; McMahon, K.; Gahlaut, R.; Thygesen, H.; Shires, M.; Roberts, S.;
Marshall, H.; Oliva, M.R.; et al. Identification and validation of DOCK4 as a potential biomarker for risk of
bone metastasis development in patients with early breast cancer. J. Pathol. 2019, 247, 381–391. [CrossRef]
30. Debruyne, D.N.; Turchi, L.; Fareh, M.; Almairac, F.; Virolle, V. DOCK4 promotes loss of proliferation in
glioblastoma progenitor cells through nuclear beta-catenin accumulation and subsequent miR-302-367 cluster
expression. Nat. Publ. Gr. 2017, 37, 241–254. [CrossRef]
31. Sundaravel, S.; Kuo, W.-L.; Jeong, J.J.; Choudhary, G.S.; Gordon-Mitchell, S.; Liu, H.; Bhagat, T.D.;
McGraw, K.L.; Gurbuxani, S.; List, A.F.; et al. Loss of Function of DOCK4 in Myelodysplastic Syndromes
Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks. Clin. Cancer Res. 2019, 25, 5638–5649.
[CrossRef] [PubMed]
32. Coleman, R.A.; Hesselink, M.K. Recent advances in lipid droplet biology. Biochim. Biophys. Acta Mol.
Cell Biol. Lipids 2017, 1862, 1129–1130. [CrossRef] [PubMed]
33. Zhu, M.; Liu, C.; Cheng, C. REACTIN: Regulatory activity inference of transcription factors underlying
human diseases with application to breast cancer. BMC Genom. 2013, 14, 504. [CrossRef] [PubMed]
34. Yim, C.Y.; Sekula, D.J.; Hever-Jardine, M.P.; Liu, X.; Warzecha, J.M.; Tam, J.; Freemantle, S.J.; Dmitrovsky, E.;
Spinella, M.J. G0S2 Suppresses Oncogenic Transformation by Repressing a MYC-Regulated Transcriptional
Program. Cancer Res. 2016, 76, 1204–1213. [CrossRef] [PubMed]
35. Mohan, D.R.; Lerario, A.M.; Else, T.; Mukherjee, B.; Almeida, M.Q.; Vinco, M.; Rege, J.; Mariani, B.M.P.;
Zerbini, M.C.N.; Mendonca, B.B.; et al. Targeted Assessment of G0S2 Methylation Identifies a Rapidly
Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma. Clin. Cancer Res. 2019, 25,
3276–3288. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 6283 20 of 22
36. Meindl, A.; Carvalho, M.R.; Herrmann, K.; Lorenz, B.; Achatz, H.; Lorenz, B.; Apfelstedt-Sylla, E.; Wittwer, B.;
Ross, M.; Meitinger, T. A gene (SRPX) encoding a sushi-repeat-containing protein is deleted in patients with
X-linked retinitis pigmentosa. Hum. Mol. Genet. 1995, 4, 2339–2346. [CrossRef]
37. Jing, P.; Kazuyoshi, N.; Masuo, Y.; Hirokazu, I.; Qin, L.; Kiyomasa, O.; Naohisa, Y.; Akira, H. Isolation of a
novel gene down-regulated by v-src. FEBS Lett. 1996, 383, 21–25. [CrossRef]
38. Yamashita, A.; Hakura, A.; Inoue, H. Suppression of anchorage-independent growth of human cancer cell
lines by the drs gene. Oncogene 1999, 18, 4777–4787. [CrossRef]
39. Shimakage, M.; Kawahara, K.; Kikkawa, N.; Sasagawa, T.; Yutsudo, M.; Inoue, H. Down-regulation of drs
mRNA in human colon adenocarcinomas. Int. J. Cancer 2000, 87, 5–11. [CrossRef]
40. Kim, C.J.; Shimakage, M.; Kushima, R.; Mukaisho, K.; Shinka, T.; Okada, Y.; Inoue, H. Down-regulation of
drs mRNA in human prostate carcinomas. Hum. Pathol. 2003, 34, 654–657. [CrossRef]
41. Shimakage, M.; Inoue, N.; Ohshima, K.; Kawahara, K.; Yamamoto, N.; Oka, T.; Tambe, Y.; Yasui, K.;
Matsumoto, K.; Yutsudo, M.; et al. Downregulation of drs mRNA expression is associated with the
progression of adult T-cell leukemia/lymphoma. Int. J. Oncol. 2007, 30, 1343–1348. [CrossRef] [PubMed]
42. Else, T.; Kim, A.C.; Sabolch, A.; Raymond, V.M.; Kandathil, A.; Caoili, E.M.; Jolly, S.; Miller, B.S.; Giordano, T.J.;
Hammer, G.D. Adrenocortical Carcinoma. Endocr. Rev. 2014, 35, 282–326. [CrossRef] [PubMed]
43. Finotello, F.; Trajanoski, Z. Quantifying tumor-infiltrating immune cells from transcriptomics data.
Cancer Immunol. Immunother. 2018, 67, 1031–1040. [CrossRef] [PubMed]
44. Becht, E.; Giraldo, N.A.; Lacroix, L.; Buttard, B.; Elarouci, N.; Petitprez, F.; Selves, J.; Laurent-puig, P.;
Sautès-fridman, C.; Fridman, W.H.; et al. Estimating the population abundance of tissue-infiltrating immune
and stromal cell populations using gene expression. Genome Biol. 2016, 17, 218. [CrossRef] [PubMed]
45. Qian, Z.; Li, Y.; Fan, X.; Zhang, C.; Wang, Y.; Jiang, T.; Liu, X. Molecular and clinical characterization of
IDH associated immune signature in lower-grade gliomas. Oncoimmunology 2018, 7, e1434466. [CrossRef]
[PubMed]
46. Ischenko, I.; Zhi, J.; Moll, U.M.; Nemajerova, A.; Petrenko, O. Direct reprogramming by oncogenic Ras and
Myc. Proc. Natl. Acad. Sci. USA 2013, 110, 3937–3942. [CrossRef]
47. Di Giorgio, E.; Clocchiatti, A.; Piccinin, S.; Sgorbissa, A.; Viviani, G.; Peruzzo, P.; Romeo, S.; Rossi, S.;
Dei Tos, A.P.; Maestro, R.; et al. MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol
3-kinase/Akt-induced transformation. Mol. Cell. Biol. 2013, 33, 4473–4491. [CrossRef]
48. Di Giorgio, E.; Franforte, E.; Cefalù, S.; Rossi, S.; Dei Tos, A.P.; Brenca, M.; Polano, M.; Maestro, R.; Paluvai, H.;
Picco, R.; et al. The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes
influences tumor aggressiveness. PLoS Genet. 2017, 13, e1006752. [CrossRef]
49. Di Giorgio, E.; Gagliostro, E.; Clocchiatti, A.; Brancolini, C. The Control Operated by the Cell Cycle Machinery
on MEF2 Stability Contributes to the Downregulation of CDKN1A and Entry into S Phase. Mol. Cell. Biol.
2015, 35, 1633–1647. [CrossRef]
50. Di Giorgio, E.; Brancolini, C. Regulation of class IIa HDAC activities: It is not only matter of subcellular
localization. Epigenomics 2016, 8, 251–269. [CrossRef]
51. Heckmann, B.L.; Zhang, X.; Xie, X.; Saarinen, A.; Lu, X.; Yang, X.; Liu, J. Defective Adipose Lipolysis and
Altered Global Energy Metabolism in Mice with Adipose Overexpression of the Lipolytic Inhibitor G 0/G
1 Switch Gene 2 (G0S2). J. Biol. Chem. 2014, 289, 1905–1916. [CrossRef] [PubMed]
52. Yim, C.Y.; Bikorimana, E.; Khan, E.; Warzecha, J.M.; Shin, L.; Rodriguez, J.; Dmitrovsky, E.; Freemantle, S.J.;
Spinella, M.J. G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway
inhibitors in breast cancer. Cell Cycle 2017, 16, 2146–2155. [CrossRef] [PubMed]
53. Fukunaga, T.; Fujita, Y.; Kishima, H.; Yamashita, T. Methylation dependent down-regulation of G0S2 leads to
suppression of invasion and improved prognosis of IDH1-mutant glioma. PLoS ONE 2018, 13, e0206552.
[CrossRef] [PubMed]
54. Cho, E.; Kwon, Y.-J.; Ye, D.-J.; Baek, H.-S.; Kwon, T.-U.; Choi, H.-K.; Chun, Y.-J. G0/G1 Switch 2 Induces Cell
Survival and Metastasis through Integrin-Mediated Signal Transduction in Human Invasive Breast Cancer
Cells. Biomol. Ther. 2019, 12, 1–12. [CrossRef]
55. Balachandran, S.; Porosnicu, M.; Barber, G.N. Oncolytic activity of vesicular stomatitis virus is effective
against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol.
2001, 75, 3474–3479. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 6283 21 of 22
56. Klampfer, L.; Huang, J.; Corner, G.; Mariadason, J.; Arango, D.; Sasazuki, T.; Shirasawa, S.; Augenlicht, L.
Oncogenic Ki-Ras Inhibits the Expression of Interferon-responsive Genes through Inhibition of STAT1 and
STAT2 Expression. J. Biol. Chem. 2003, 278, 46278–46287. [CrossRef]
57. Battcock, S.M.; Collier, T.W.; Zu, D.; Hirasawa, K. Negative regulation of the alpha interferon-induced
antiviral response by the Ras/Raf/MEK pathway. J. Virol. 2006, 80, 4422–4430. [CrossRef]
58. Komatsu, Y.; Christian, S.L.; Ho, N.; Pongnopparat, T.; Licursi, M.; Hirasawa, K. Oncogenic Ras inhibits
IRF1 to promote viral oncolysis. Oncogene 2015, 34, 3985–3993. [CrossRef]
59. Komatsu, Y.; Hirasawa, K.; Christian, S.L. Global gene analysis identifying genes commonly regulated by the
Ras/Raf/MEK and type I IFN pathways. Genom. Data 2015, 4, 84–87. [CrossRef]
60. Jonak, G.J.; Knight, E. Selective reduction of c-myc mRNA in Daudi cells by human beta interferon. Proc. Natl.
Acad. Sci. USA 1984, 81, 1747–1750. [CrossRef]
61. Dani, C.; Mechti, N.; Piechaczyk, M.; Lebleu, B.; Jeanteur, P.; Blanchard, J.M. Increased rate of degradation of
c-myc mRNA in interferon-treated Daudi cells. Proc. Natl. Acad. Sci. USA 1985, 82, 4896–4899. [CrossRef]
[PubMed]
62. Schlee, M.; Hölzel, M.; Bernard, S.; Mailhammer, R.; Schuhmacher, M.; Reschke, J.; Eick, D.; Marinkovic, D.;
Wirth, T.; Rosenwald, A.; et al. c-MYC activation impairs the NF-κB and the interferon response: Implications
for the pathogenesis of Burkitt’s lymphoma. Int. J. Cancer 2007, 120, 1387–1395. [CrossRef] [PubMed]
63. Schlee, M.; Schuhmacher, M.; Hölzel, M.; Laux, G.; Bornkamm, G.W. c-MYC Impairs Immunogenicity of
Human B Cells. Adv. Cancer Res. 2007, 97, 167–188. [PubMed]
64. Polioudakis, D.; Bhinge, A.A.; Killion, P.J.; Lee, B.; Abell, N.S.; Iyer, V.R. A Myc–microRNA network promotes
exit from quiescence by suppressing the interferon response and cell-cycle arrest genes. Nucleic Acids Res.
2013, 41, 2239–2254. [CrossRef]
65. Wee, Z.N.; Li, Z.; Lee, P.L.; Lee, S.T.; Lim, Y.P.; Yu, Q. EZH2-Mediated Inactivation of
IFN-γ-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer. Cell Rep.
2014, 8, 204–216. [CrossRef]
66. Kim, T.W.; Hong, S.; Lin, Y.; Murat, E.; Joo, H.; Kim, T.; Pascual, V.; Liu, Y. Transcriptional Repression of IFN
Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendritic Cells.
J. Immunol. 2016, 197, 3348–3359. [CrossRef]
67. Layer, J.P.; Kronmüller, M.T.; Quast, T.; Boorn-Konijnenberg, D.V.D.; Effern, M.; Hinze, D.; Althoff, K.;
Schramm, A.; Westermann, F.; Peifer, M.; et al. Amplification of N-Myc is associated with a T-cell-poor
microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine
expression. Oncoimmunology 2017, 6, e1320626. [CrossRef]
68. Zou, J.; Zhuang, M.; Yu, X.; Li, N.; Mao, R.; Wang, Z.; Wang, J.; Wang, X.; Zhou, H.; Zhang, L.; et al.
MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells. Mol. Immunol.
2018, 101, 203–209. [CrossRef]
69. Topper, M.J.; Vaz, M.; Chiappinelli, K.B.; DeStefano Shields, C.E.; Niknafs, N.; Yen, R.C.; Wenzel, A.; Hicks, J.;
Ballew, M.; Stone, M.; et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and
Treating Lung Cancer. Cell 2017, 171, 1284–1300. [CrossRef]
70. Rathi, A.V.; Cantalupo, P.G.; Sarkar, S.N.; Pipas, J.M. Induction of interferon-stimulated genes by Simian
virus 40 T antigens. Virology 2010, 406, 202–211. [CrossRef]
71. Nozawa, H.; Oda, E.; Nakao, K.; Ishihara, M.; Ueda, S.; Yokochi, T.; Ogasawara, K.; Nakatsuru, Y.; Shimizu, S.;
Ohira, Y.; et al. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras
transgene or nullizygosity for p53. Genes Dev. 1999, 13, 1240–1245. [CrossRef] [PubMed]
72. Sica, A.; Allavena, P.; Mantovani, A. Cancer related inflammation: The macrophage connection. Cancer Lett.
2008, 267, 204–215. [CrossRef] [PubMed]
73. Nagarsheth, N.; Wicha, M.S.; Zou, W. Chemokines in the cancer microenvironment and their relevance in
cancer immunotherapy. Nat. Rev. Immunol. 2017, 17, 559–572. [CrossRef] [PubMed]
74. Chow, M.T.; Luster, A.D. Chemokines in Cancer. Cancer Immunol. Res. 2014, 2, 1125–1131. [CrossRef]
[PubMed]
75. Spranger, S.; Gajewski, T.F. Impact of oncogenic pathways on evasion of antitumour immune responses.
Nat. Rev. Cancer 2018, 18, 139–147. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 6283 22 of 22
76. Gauthier, L.R.; Charrin, B.C.; Borrell-Pagès, M.; Dompierre, J.P.; Rangone, H.; Cordelières, F.P.; De Mey, J.;
MacDonald, M.E.; Leßmann, V.; Humbert, S.; et al. Huntingtin Controls Neurotrophic Support and Survival
of Neurons by Enhancing BDNF Vesicular Transport along Microtubules. Cell 2004, 118, 127–138. [CrossRef]
77. Dai, M. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data.
Nucleic Acids Res. 2005, 33, e175. [CrossRef]
78. Irizarry, R.A. Exploration, normalization, and summaries of high density oligonucleotide array probe level
data. Biostatistics 2003, 4, 249–264. [CrossRef]
79. Ritchie, M.E.; Phipson, B.; Wu, D.; Hu, Y.; Law, C.W.; Shi, W.; Smyth, G.K. limma powers differential
expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015, 43, e47. [CrossRef]
80. Jacobsen, A. Cgdsr: R-Based API for Accessing the MSKCC Cancer Genomics Data Server (CGDS).
Version 1.3.0. Available online: http://CRAN.R-project.org/package=cgdsr (accessed on 30 October 2019).
81. Therneau, T. A package for survival analysis. In S. Version 2.44-1.1. Available online: https://CRAN.R-
project.org/package=survivaL (accessed on 30 October 2019).
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
